Testosterone replacement therapy (TRT) might be suitable for men with hypogonadism who also have a history of prostate cancer, but more research is needed, according to a group of Canadian and American scientists.
Laboratory testing for testosterone (T) levels should be standardized and a hypogonadism diagnosis should be made using both a blood test and a physical exam, a panel of experts says.
Men with erectile dysfunction (ED) might have increased cardiovascular risk when their testosterone levels fall below 12 nmol/L, according to a recent Journal of Sexual Medicine study.
For some time, there has been concern among physicians that testosterone therapy either leads to prostate cancer or causes undiagnosed prostate cancer to progress. These beliefs have been shown to be a myth; however, many physicians still cite this concern as the main reason for not prescribing testosterone therapy. The current study aimed to address these concerns and describe the long-term outcomes for 1,365 men who tried different forms of testosterone therapy as part of the UK Androgen Study (UKAS).